BEIJING, June 30 (Xinhua) -- AstraZeneca, the British pharmaceutical giant, is optimistic about China's economic prospects and health industry development, and will continue to increase its investment in China, said Leon Wang, executive vice president of AstraZeneca, Chinanews.com reported on Wednesday.
Over the past 30 years, AstraZeneca has grown rapidly in China with its R&D investment continuing increasing. In 2021, the company has upgraded its Global R&D (China) center in Shanghai, which will facilitate the early development and incubation of more first-in-class new drugs in China.
According to Leon Wang, AstraZeneca is also preparing to establish the first bioanalytical laboratory for innovative targeted biotherapies operated in China by a multinational pharmaceutical company, aiming to support the development of innovative targeted biologic drugs projects in China and around the world.
AstraZeneca currently has been undertaking more than 150 research and development (R&D) projects in China. In the future, the company will continue to pool global wisdom and promote innovation and incubation in China to benefit more patients, Wang said.
(Edited by Gao Jingyan with Xinhua Silk Road, gaojingyan@xinhua.org)
A single purchase
